Literature DB >> 33707593

Atrial high‑rate episodes and risk of major adverse cardiovascular events in patients with dual chamber permanent pacemakers: a retrospective study.

Wei-Da Lu1, Ju-Yi Chen2.   

Abstract

Patients with atrial high-rate episodes (AHRE) are at higher risk of major adverse cardiovascular events (MACE). The cutoff threshold for AHRE duration for MACE, with/without history of atrial fibrillation (AF) or myocardial infarction (MI), is unknown. A total of 481 consecutive patients with/without history of AF or MI receiving dual-chamber pacemaker implantation were included. The primary outcome was a composite endpoint of MACE after AHRE ≥ 5 min, ≥ 6 h, and ≥ 24 h. AHRE was defined as > 175 bpm (MEDTRONIC) or > 200 bpm (BIOTRONIK) lasting ≥ 5 min. Cox regression analysis with time-dependent covariates was conducted. Patients' mean age was 75.3 ± 10.7 years and 188 (39.1%) developed AHRE ≥ 5 min, 115 (23.9%) ≥ 6 h, and 83 (17.3%) ≥ 24 h. During follow-up (median 39.9 ± 29.8 months), 92 MACE occurred (IR 5.749%/year, 95% CI 3.88-5.85). AHRE ≥ 5 min (HR 5.252, 95% CI 2.575-10.715, P < 0.001) and ≥ 6 h (HR 2.548, 95% CI 1.284-5.058, P = 0.007) was independently associated with MACE, but not AHRE ≥ 24 h. Patients with history of MI (IR 17.80%/year) had higher MACE incidence than those without (IR 3.77%/year, p = 0.001). Significant differences were found between MACE patients with/without history of AF in AHRE ≥ 5 min but not AHRE ≥ 6 h or ≥ 24 h. Patients with dual-chamber pacemakers who develop AHRE have increased risk of MACE, particularly after history of AF or MI.

Entities:  

Mesh:

Year:  2021        PMID: 33707593      PMCID: PMC7952691          DOI: 10.1038/s41598-021-85301-7

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  25 in total

1.  Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation.

Authors:  Christina Ji-Young Lee; Thomas Alexander Gerds; Nicholas Carlson; Anders Nissen Bonde; Gunnar Hilmar Gislason; Morten Lamberts; Jonas Bjerring Olesen; Jannik Langtved Pallisgaard; Morten Lock Hansen; Christian Torp-Pedersen
Journal:  J Am Coll Cardiol       Date:  2018-07-03       Impact factor: 24.094

2.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas
Journal:  Eur Heart J       Date:  2016-08-27       Impact factor: 29.983

3.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas; Stefan Agewall; John Camm; Gonzalo Baron Esquivias; Werner Budts; Scipione Carerj; Filip Casselman; Antonio Coca; Raffaele De Caterina; Spiridon Deftereos; Dobromir Dobrev; José M Ferro; Gerasimos Filippatos; Donna Fitzsimons; Bulent Gorenek; Maxine Guenoun; Stefan H Hohnloser; Philippe Kolh; Gregory Y H Lip; Athanasios Manolis; John McMurray; Piotr Ponikowski; Raphael Rosenhek; Frank Ruschitzka; Irina Savelieva; Sanjay Sharma; Piotr Suwalski; Juan Luis Tamargo; Clare J Taylor; Isabelle C Van Gelder; Adriaan A Voors; Stephan Windecker; Jose Luis Zamorano; Katja Zeppenfeld
Journal:  Eur J Cardiothorac Surg       Date:  2016-09-23       Impact factor: 4.191

4.  Atrial high-rate episodes and risk of major adverse cardiovascular events in patients with cardiac implantable electronic devices.

Authors:  Daniele Pastori; Kazuo Miyazawa; Yanguang Li; Orsolya Székely; Farhan Shahid; Alessio Farcomeni; Gregory Y H Lip
Journal:  Clin Res Cardiol       Date:  2019-05-29       Impact factor: 5.460

Review 5.  Atrial Fibrillation and Mechanisms of Stroke: Time for a New Model.

Authors:  Hooman Kamel; Peter M Okin; Mitchell S V Elkind; Costantino Iadecola
Journal:  Stroke       Date:  2016-01-19       Impact factor: 7.914

6.  Atrial fibrillation, progression of coronary atherosclerosis and myocardial infarction.

Authors:  Ozgur Bayturan; Rishi Puri; E Murat Tuzcu; Mingyuan Shao; Kathy Wolski; Paul Schoenhagen; Samir Kapadia; Steven E Nissen; Prashanthan Sanders; Stephen J Nicholls
Journal:  Eur J Prev Cardiol       Date:  2016-11-12       Impact factor: 7.804

7.  Atrial fibrillation and the risk of myocardial infarction.

Authors:  Elsayed Z Soliman; Monika M Safford; Paul Muntner; Yulia Khodneva; Farah Z Dawood; Neil A Zakai; Evan L Thacker; Suzanne Judd; Virginia J Howard; George Howard; David M Herrington; Mary Cushman
Journal:  JAMA Intern Med       Date:  2014-01       Impact factor: 21.873

Review 8.  2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension.

Authors:  Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis Clement; Antonio Coca; Giovanni De Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre Kjeldsen; Reinhold Kreutz; Stéphane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland Schmieder; Evgeny Shlyakhto; Konstantinos Tsioufis; Victor Aboyans; Ileana Desormais
Journal:  Blood Press       Date:  2018-12       Impact factor: 2.835

9.  Statins reduce new-onset atrial fibrillation after acute myocardial infarction: A nationwide study.

Authors:  Chien-Hao Tseng; Wen-Jung Chung; Chen-Yu Li; Tzu-Hsien Tsai; Chien-Ho Lee; Shu-Kai Hsueh; Chia-Chen Wu; Cheng-I Cheng
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

10.  Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.

Authors:  Georg Gelbenegger; Marek Postula; Ladislav Pecen; Sigrun Halvorsen; Maciej Lesiak; Christian Schoergenhofer; Bernd Jilma; Christian Hengstenberg; Jolanta M Siller-Matula
Journal:  BMC Med       Date:  2019-11-04       Impact factor: 8.775

View more
  3 in total

1.  Atrial high-rate episodes predict major adverse cardio/cerebrovascular events in patients with cardiac implantable electrical devices.

Authors:  Ju-Yi Chen; Tse-Wei Chen; Wei-Da Lu
Journal:  Sci Rep       Date:  2021-09-23       Impact factor: 4.379

Review 2.  How should I treat patients with subclinical atrial fibrillation and atrial high-rate episodes? Current evidence and clinical importance.

Authors:  Fabienne Kreimer; Andreas Mügge; Michael Gotzmann
Journal:  Clin Res Cardiol       Date:  2022-03-15       Impact factor: 6.138

3.  The Differential Prognostic Impact of Long-Duration Atrial High-Rate Episodes Detected by Cardiac Implantable Electronic Devices between Patients with and without a History of Atrial Fibrillation.

Authors:  Hironori Ishiguchi; Yasuhiro Yoshiga; Akihiko Shimizu; Takeshi Ueyama; Makoto Ono; Masakazu Fukuda; Takayoshi Kato; Shohei Fujii; Masahiro Hisaoka; Tomoyuki Uchida; Takuya Omuro; Takayuki Okamura; Shigeki Kobayashi; Masafumi Yano
Journal:  J Clin Med       Date:  2022-03-21       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.